DOD Pancreatic Cancer, Translational Research Partnership Award

Active
Yes
Status
Posted
Published Date
April 29th, 2024
Close Date
October 3rd, 2024
Total Funding
$4,800,000.00
Expected No. Awards
4
Opportunity No.
HT942524PCARPTRPA

Agency

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The Department of the Army, through the US Army Medical Research Acquisition Activity (USAMRAA), has posted a federal grant opportunity titled "DOD Pancreatic Cancer, Translational Research Partnership Award". This grant aims to support partnerships between clinicians and research scientists to accelerate the translation of promising ideas in pancreatic cancer towards clinical applications. The Translational Research Partnership Award seeks to foster collaborations between two independent investigators to address a central problem or question in pancreatic cancer that would be difficult to achieve through separate efforts. One partner in the collaboration must be a research scientist, while the other partner must be a clinician investigator. The award encourages the inclusion of experts from outside the pancreatic cancer field. The proposed projects should demonstrate the potential to have a significant impact on pancreatic cancer research and/or patient care. They should also leverage clinical information to address knowledge gaps, validate research findings, expand upon transformative results, and investigate novel findings. The application should provide evidence of the reciprocal transfer of information between basic and clinical science. The Translational Research Partnership Award requires the availability of necessary specimens, data, and/or interventions. Preliminary data relevant to pancreatic cancer and the proposed research project are required, although they do not necessarily need to be derived from studies of pancreatic cancer. The success of the project relies on the unique skills and contributions of each partner, and the proposed study must include plans for communication, coordination of research progress and results, and data transfer. This grant opportunity has an estimated total program funding of $4,800,000 and expects to make four awards. The closing date for applications is October 3, 2024. For more information and application submission requirements, interested applicants can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507. By providing a comprehensive summary of this federal grant notice, we hope to support potential applicants in understanding the purpose and requirements of the DOD Pancreatic Cancer, Translational Research Partnership Award.

Description

The FY24 PCARP Translational Research Partnership Award supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. This award supports the development of translational research collaborations between two independent investigators to address a central problem or question in pancreatic cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must function as a research scientist and the other partner as a clinician investigator. It should be clear that both have had equal intellectual input in the design of the research project. Projects involving convergence science partnerships are strongly encouraged. At least one partner must have expertise either in pancreatic cancer research or pancreatic cancer patient care. Inclusion of experts from outside the pancreatic cancer field is encouraged. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism. Full support for large-scale clinical trials is not expected; retrospective tissue analysis, correlative studies, or small pilot clinical trials are permitted.Significant features of the Translational Research Partnership Award:Partnership: The success of the project should depend on the unique skills and contributions of each partner.Translation: The application should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan. Translational research may include correlative studies and/or development of or use of annotated biorepositories. The application should demonstrate how the study will leverage clinical information to address knowledge gaps in resulting outcomes, validate key research findings, expand upon potentially transformative results, and/or investigate novel findings.Impact: The proposed research should indicate the potential to have a significant impact on pancreatic cancer research and/or patient care and have the potential to accelerate the movement of promising ideas (in prevention, diagnosis, detection, prognosis, treatment, and/or survivorship) into clinical applications.Feasibility: The application should demonstrate that the investigators have access to the necessary specimens, data, and/or intervention, as applicable.Preliminary Data: Published and/or unpublished results from the laboratory of the Principal Investigators (PIs) or collaborators named on the application that are relevant to pancreatic cancer and the proposed research project, are required.Preliminary data to support the feasibility of the research hypothesis(es) and research approaches are required; however, these data do not necessarily need to be derived from studies of pancreatic cancer.Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patients and anecdotal data. The ultimate goal of translational research is to move a concept or observation forward into clinical application that is relevant to active-duty Service Members, Veterans, other military beneficiaries, and the American public. However, translational research should not be viewed as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. There should be an intellectual synergistic partnership between the clinic and the laboratory.The success of the project must be supported by the unique skills and contributions of each partner. The proposed study must include clearly stated plans for interactions between the PIs and the institutions involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.The Translational Research Partnership Award requires two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development and execution of the proposed research project. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI, refer to Section II.D.2, Content and Form of the Application Submission.

Contact Information

Attachments
555 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

DOD Pancreatic Cancer, Idea Development Award
Dept. of the Army -- USAMRAA
The Department of the Army -- USAMRAA is offering a grant opportunity titled "DOD Pancreatic Cancer, Idea Development Award". This grant aims to support the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements in improving outcomes for individuals with pancreatic cancer. The grant seeks to fund projects that make important and original contributions to advancing the understanding of pancreatic cancer and ultimately lead to improved outcomes for patients. The research should be innovative and may challenge existing paradigms or utilize new perspectives, methods, or technologies. The grant encourages the inclusion of personnel with experience in pancreatic cancer research and the use of preliminary data to support the proposed research. Additionally, the grant offers a higher level of funding for applications that propose to partner an experienced PI with an Early-Career Investigator wishing to pursue a career in pancreatic cancer research. The deadline for application submission is October 3, 2024. For more information, contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
DOD Pancreatic Cancer, Focused Pilot Award
Dept. of the Army -- USAMRAA
The Department of the Army -- USAMRAA has posted a grant opportunity titled "DOD Pancreatic Cancer, Focused Pilot Award". This grant aims to support impactful and innovative concepts in pancreatic cancer research that can lead to significant advancements in patients' overall quality of life. The grant is focused on two patient-centered areas of research: access to healthcare and mental health/cancer-related outcomes and quality of life. The grant encourages studies on behaviors affecting access to healthcare, correlations between mental health and cancer outcomes, strategies to overcome psycho-social issues, behavioral studies on quality of life and decision-making, and development of nutritional or educational interventions for symptom management. The grant does not require preliminary data but expects a well-formulated, testable hypothesis based on strong scientific rationale. Clinical research studies are allowed, but interventional clinical trials, basic research, and preclinical animal studies are not supported. The proposed research should have a significant impact on improving outcomes and quality of life for individuals with pancreatic cancer. Innovation in study concept, research methods or technology, and adaptations of existing methods or technologies is highly encouraged. The grant has an estimated total program funding of $1,280,000 and expects to make 4 awards. The closing date for applications is October 3, 2024. For more information, you can contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.
DOD Lung Cancer, Translational Research Award
Dept. of the Army -- USAMRAA
The Department of the Army -- USAMRAA has posted a grant opportunity titled "DOD Lung Cancer, Translational Research Award". This grant aims to support advanced translational research in lung cancer, with the goal of transforming promising ideas into clinical applications. Translational research involves integrating basic science and clinical observations to move concepts or observations forward into clinical application. The grant will fund a broad range of translational studies, excluding research applications solely focused on mesothelioma. There are two funding levels available for different types of research projects. Funding Level 1 includes advanced preclinical studies, late-stage preclinical work, correlative studies, and projects that develop endpoints for clinical trials. Funding Level 2 supports pilot clinical trials to inform the next step in translational research. The grant requires preliminary lung cancer relevant data to support the feasibility of the research hypotheses and approaches. The close date for this grant opportunity is August 7, 2024. For more information, you can contact the CDMRP Help Desk at help@eBRAP.org or by phone at 301-682-5507.